<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00266058</url>
  </required_header>
  <id_info>
    <org_study_id>AAKE99</org_study_id>
    <nct_id>NCT00266058</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study Between Antimalarial and Anti-HIV Medications</brief_title>
  <official_title>Pharmacokinetic Interactions Between Antiretroviral Agents, Lopinavir/Ritonavir and Efavirenz and Antimalarial Drug Combination, Artemether/Lumefantrine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether taking certain anti-HIV medicines with&#xD;
      certain antimalarial medicines affects the amount of the medicines in the blood.&#xD;
&#xD;
      The study medicines that will be used are artemether/lumefantrine (antimalarial medication)&#xD;
      and lopinavir/ritonavir or efavirenz (anti-HIV medications). Artemether/lumefantrine is not&#xD;
      approved by the United States Food and Drug Administration (FDA) but is recommended as&#xD;
      standard of care medical treatment for malaria in Africa and Asia. Lopinavir/ritonavir and&#xD;
      efavirenz are approved by the FDA. Artemether/lumefantrine and lopinavir/ritonavir or&#xD;
      efavirenz may need to be used together to treat children in Africa and Asia. We seek to learn&#xD;
      about whether or not the use of these medicines together results in a change in blood levels&#xD;
      of any of these medicines. The information obtained from this study will help doctors to&#xD;
      provide a better treatment to children and adults with malaria and HIV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study involves 5 non-consecutive overnight stays and 14 additional outpatient visits at&#xD;
      the San Francisco General Hospital Research Center.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic assessment of potential drug-drug interactions of antimalarials and antiretroviral agents.</measure>
    <time_frame>Intensive serial PK sampling of antimalarials conducted on study day 4 (without antiretrovirals) and study day 31 (in the context of antiretrovirals</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>HIV Infections</condition>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Lopinavir/ritonavir, artemethr/lumefantrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretrovirals lopinavir and ritonavir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>efavirenz, artemether, lumefantrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretroviral efavirenz.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine</intervention_name>
    <description>participants receive a total of 6 doses of artemether(80mg)/lumefantrine(480mg)for baseline PK evaluation. This is followed by a 26-day course of either efavirenz(600mg) once daily or lopinavir/ritonavir (400mg/100mg) twice daily and additional 6 doses of artemether/lumefantrine to determine the pharmacokinetics of the antimalarial medications in the context of antiretrovirals. The participants undergo at least a 14 day washout period (between the last baseline PK blood draw and the initiation of antiretrovirals)</description>
    <arm_group_label>Lopinavir/ritonavir, artemethr/lumefantrine</arm_group_label>
    <arm_group_label>efavirenz, artemether, lumefantrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Absence of HIV infection prior to study entry&#xD;
&#xD;
          -  Within 20% (+/-) of ideal body weight and must weigh at least 50kg&#xD;
&#xD;
          -  Healthy subjects without evidence of acute or chronic illnesses, including diabetes,&#xD;
             high blood pressure, coronary artery disease, psychiatric illnesses, liver or kidney&#xD;
             impairment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of illicit drugs or alcohol that could interfere with the completion of the study.&#xD;
&#xD;
          -  Use of any over- the- counter or prescribed drugs unless approved by the principal&#xD;
             investigator or study physician.&#xD;
&#xD;
          -  Pregnant or breast- feeding.&#xD;
&#xD;
          -  History of acute or chronic illnesses, such as diabetes, high blood pressure, coronary&#xD;
             artery disease, psychiatric illnesses, liver or kidney impairment.&#xD;
&#xD;
          -  Evidence of acute illness.&#xD;
&#xD;
          -  Family history of congenital prolongation of QTc interval or with any conditions known&#xD;
             to prolong QTc interval, such as cardiac arrhythmias, bradycardia or severe heart&#xD;
             disease&#xD;
&#xD;
          -  History of electrolyte abnormalities.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesca Aweeka, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>December 14, 2005</study_first_submitted>
  <study_first_submitted_qc>December 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2005</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Fran Aweeka</investigator_full_name>
    <investigator_title>Prinicpal Investigator</investigator_title>
  </responsible_party>
  <keyword>healthy</keyword>
  <keyword>controls</keyword>
  <keyword>research</keyword>
  <keyword>clinical</keyword>
  <keyword>study</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>PK</keyword>
  <keyword>HIV</keyword>
  <keyword>malaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemether, Lumefantrine Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

